2. Search Result
Search Result
Results for "

TG

" in MedChemExpress (MCE) Product Catalog:

80

Inhibitors & Agonists

1

Fluorescent Dye

2

Peptides

3

Inhibitory Antibodies

11

Natural
Products

1

Recombinant Proteins

15

Isotope-Labeled Compounds

3

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2962
    Transglutaminase, Streptoverticillium mobaraense

    TG

    		 Others Infection Inflammation/Immunology
    Transglutaminase, Streptoverticillium mobaraense (TG) is an enzyme that forms crosslinks between protein molecules. Transglutaminase catalyses the formation of an isopeptide bond between the group of γ-carboxamides of glutamine residues and the first-order ε-amine groups of different compounds. Transglutaminase is involved in many physiological processes, including coagulation, antibacterial immune reactions and photosynthesis .
    Transglutaminase, Streptoverticillium mobaraense
  • HY-111298
    TG 41

    		GABA Receptor Neurological Disease
    TG 41 is positive modulator of GABAA receptor. TG 41 enhances the binding both of GABA and of Flunitrazepam to rat cerebral cortical membranes .
    <em>TG</em> 41
  • HY-18970
    TG6-129

    TG6-129 is a selective antagonist of the EP2 receptor. TG6-129 reduces the expression of inflammatory factors induced by butaprost in P388D1 macrophages .
    <em>TG</em>6-129
  • HY-160132
    TG-2-IN-4

    		Glutaminase Inflammation/Immunology
    TG-2-IN-4 (compound 8) is a transglutaminase 2 (TG2) inhibitor with an IC50 <0.5 mM. TG-2-IN-4 can be used for the research of inflammatory disorder .
    <em>TG</em>-2-IN-4
  • HY-122631
    TG693

    		CDK Others
    TG693 is an orally active inhibitor of CLK1. TG693 regulates the mutated exon 31 of the dystrophin gene in vivo. TG693 is used in Duchenne muscular dystrophy (DMD) research .
    <em>TG</em>693
  • HY-137438
    Edralbrutinib

    TG-1701

    		 Btk Cancer
    Edralbrutinib (TG-1701) is a potent BTK inhibitor .
    Edralbrutinib
  • HY-102073
    TG53

    		Glutaminase Integrin FAK Src Cancer
    TG53 is a potent inhibitor of tissue transglutaminase (TG2) and fibronectin (FN) protein-protein interaction. TG53 inhibits formation of a complex with integrin β1 and activation of FAK and c-Src during SKOV3 cell attachment onto FN. TG53 can be used for ovarian cancer research .
    <em>TG</em>53
  • HY-117678
    TG-2-IN-1

    		Glutaminase Others
    TG-2-IN-1 (Compound D003) is a transglutaminase-2 (TGM-2) inhibitor. TG-2-IN-1 can be used for the research of myopia .
    <em>TG</em>-2-IN-1
  • HY-18971
    TG4-155
    1 Publications Verification
    TG4-155 is a potent, brain-permeant and selective EP2 receptor antagonist with a Ki of 9.9 nM . TG4-155 shows low nanomolar antagonist activity against only EP2 and DP1 . TG4-155 has an EP2 Schild KB of 2.4 nM and displays 550-4750-fold selectivity for EP2 over EP1, EP3, EP4 and IP, but only 14-fold selectivity against the DP1 receptor .
    <em>TG</em>4-155
  • HY-10186
    TG 100801
    1 Publications Verification

    		 VEGFR FGFR PDGFR Src Cancer
    TG 100801 is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
    <em>TG</em> 100801
  • HY-10187
    TG 100801 Hydrochloride

    		VEGFR FGFR PDGFR Src Cancer
    TG 100801 Hydrochloride is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
    <em>TG</em> 100801 Hydrochloride
  • HY-19867A
    Burixafor hydrobromide

    TG-0054 hydrobromide

    		 CXCR Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent antagonist of CXCR4 and a well anti-angiogenic drug that is of potential value in treating choroid neovascularization . Burixafor hydrobromide (TG-0054 hydrobromide) mobilizes mesenchymal stem cells, attenuates inflammation, and preserves cardiac systolic function in a porcine model of myocardial infarction .
    Burixafor hydrobromide
  • HY-10111
    TG100-115
    2 Publications Verification

    		 PI3K Cardiovascular Disease Cancer
    TG100-115 is a selective PI3Kγ/PI3Kδ inhibitor with IC50s of 83 and 235 nM, respectively.
    <em>TG</em>100-115
  • HY-13514
    TG 100713
    2 Publications Verification

    		 PI3K Cancer
    TG 100713 is an inhibitor of PI3K, with IC50s of 24, 50, 165, and 215 nM for PI3Kδ, γ, α and β isoforms respectively .
    <em>TG</em> 100713
  • HY-14956
    Nemonoxacin

    TG-873870

    		 Antibiotic Bacterial Infection Inflammation/Immunology
    Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia .
    Nemonoxacin
  • HY-15338
    TG003
    3 Publications Verification

    		 CDK Cancer
    TG003 is a potent inhibitor of Clk1/Sty; inhibits Clk1 and Clk4 with IC50 values of 20 and 15 nM, respectively .
    <em>TG</em>003
  • HY-16978
    TG6-10-1
    5+ Cited Publications

    		 5-HT Receptor Prostaglandin Receptor Neurological Disease Endocrinology
    TG6-10-1 is an EP2 antagonist, shows low-nanomolar antagonist activity against only EP2, >300-fold selectivity over human EP3, EP4, and IP receptors, 100-fold selectivity over EP1 receptors .
    <em>TG</em>6-10-1
  • HY-RS14432
    TG Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    TG Human Pre-designed siRNA Set A contains three designed siRNAs for TG gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TG Human Pre-designed siRNA Set A
    TG Human Pre-designed siRNA Set A
  • HY-P99538
    Ublituximab

    LFB-R603; TG-1101; TGTX-1101

    		 CD20 Cancer
    Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects .
    Ublituximab
  • HY-111023
    Nemonoxacin malate

    TG-873870 malate

    		 Antibiotic Bacterial Infection
    Nemonoxacin (TG-873870) malate is a nonfluorinated quinolone antibiotic. Nemonoxacin malate has broad-spectrum activity against Gram-positive, Gram-negative and atypical pathogens. Nemonoxacin malate can inhibit drug-resistant Streptococcus pneumoniae and (HY-121544) Methicillin-resistant Staphylococcus aureus. Nemonoxacin malate can be used for the research of community-acquired pneumonia .
    Nemonoxacin malate
  • HY-10185
    TG 100572 Hydrochloride
    2 Publications Verification

    		 Src VEGFR FGFR PDGFR Inflammation/Immunology
    TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
    <em>TG</em> 100572 Hydrochloride
  • HY-10184
    TG 100572

    		Src VEGFR PDGFR FGFR Cancer
    TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
    <em>TG</em> 100572
  • HY-P99833
    Cosibelimab

    CK-301; TG-1501

    		 PD-1/PD-L1 Cancer
    Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 + cell lines, including lymphoma cells .
    Cosibelimab
  • HY-10410
    TG101209
    4 Publications Verification

    		 FLT3 JAK RET Autophagy Apoptosis Cancer
    TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET with IC50 of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.
    <em>TG</em>101209
  • HY-10409
    Fedratinib
    Maximum Cited Publications
    31 Publications Verification

    TG-101348; SAR 302503

    		 JAK Apoptosis Cancer
    Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .
    Fedratinib
  • HY-10409A
    Fedratinib hydrochloride hydrate
    Maximum Cited Publications
    31 Publications Verification

    TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate

    		 JAK Apoptosis Cancer
    Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .
    Fedratinib hydrochloride hydrate
  • HY-15163
    Zotiraciclib

    TG02; SB1317

    		 JAK CDK FLT3 Cancer
    Zotiraciclib (TG02) is an orally active potent inhibitor of CDK2, JAK2 and FLT3 with IC50 values of 13, 73, and 56 nM, respectively. Zotiraciclib can be used for the research of advanced leukemias and multiple myeloma .
    Zotiraciclib
  • HY-14956S
    Nemonoxacin-d3

    TG-873870-d3

    		 Bacterial Inflammation/Immunology
    Nemonoxacin-d3 is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia[1][2][3].
    Nemonoxacin-d3
  • HY-14956S2
    Nemonoxacin-d4

    TG-873870-d4

    		 Bacterial Inflammation/Immunology
    Nemonoxacin-d4 is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia[1][2][3].
    Nemonoxacin-d4
  • HY-N11286
    Tridocosahexaenoylglycerol

    TG-DHA; Meganol D

    		 Others Neurological Disease Metabolic Disease Inflammation/Immunology
    Tridocosahexaenoylglycerol (TG-DHA) is an orally active dietary supplement that improves autoimmune encephalomyelitis in mice. Tridocosahexaenoylglycerol shows beneficial effects on neurodegenerative diseases and also improves macular function in diabetic retinopathy. Tridocosahexaenoylglycerol can be used for research on neurological diseases, inflammatory immune diseases, and metabolic diseases .
    Tridocosahexaenoylglycerol
  • HY-14956S1
    Nemonoxacin-d3-1

    TG-873870-d3-1

    		 Bacterial Inflammation/Immunology
    Nemonoxacin-d3-1 is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia[1][2][3].
    Nemonoxacin-d3-1
  • HY-163165S
    16:0-19:2-16:0 TG-d5

    		Isotope-Labeled Compounds Metabolic Disease
    16:0-19:2-16:0 TG-d5 is the deuterium labeled triacylglycerols.
    16:0-19:2-16:0 <em>TG</em>-d5
  • HY-15338A
    (E/Z)-TG003

    		CDK Cancer
    (E/Z)-TG003 is a racemic compound of (Z)-TG003 and (E)-TG003. (Z)-TG003 is a potent inhibitor of Clk1/Sty; inhibits Clk1 and Clk4 with IC50 values of 20 and 15 nM, respectively .
    (E/Z)-<em>TG</em>003
  • HY-155102
    PROTAC TG2 degrader-2

    		PROTACs Glutaminase Cancer
    PROTAC TG2 degrader-2 (compound 7) is a selective, competitive degrader targeting Transglutaminase 2 (TG2), with Kd > 100 μM. PROTAC TG2 degrader-2 inhibits the cell migration and decreases the level of TG2 in ovarian cancer cells. PROTAC TG2 degrader-2 can be used for ovarian cancer study .
    PROTAC <em>TG</em>2 degrader-2
  • HY-155643
    PROTAC TG2 degrader-1

    		PROTACs Glutaminase Cancer
    PROTAC TG2 degrader-1 (compound 11) is a von Hippel-Lindau (VHL)-based PROTAC targeting tissue transglutaminase (TG2) with a KD of 68.9 μM. PROTAC TG2 degrader-1 reduces TG2 in ovarian cancer cells in a proteasome-dependent manner .
    PROTAC <em>TG</em>2 degrader-1
  • HY-149257
    HAT-SIL-TG-1&AT

    		JAK STAT Cancer
    HAT-SIL-TG-1&AT is a Janus tyrosine kinase (JAK) inhibitor with antitumor effects. HAT-SIL-TG-1&AT is the hypoxia-activated prodrug, witch inhibits JAK-STAT signaling in tumor tissue. And HAT-SIL-TG-1&AT inhibits HEL cells proliferation and downregulated phosphorylated STAT3/5 under hypoxic conditions .
    HAT-SIL-<em>TG</em>-1&AT
  • HY-146912S
    14:0-16:1-14:0 TG-d5

    		Isotope-Labeled Compounds Others
    14:0-16:1-14:0 TG-d5 is deuterium labeled 14:0-16:1-14:0 TG.
    14:0-16:1-14:0 <em>TG</em>-d5
  • HY-146914S
    16:0-18:0-16:0 TG-d5

    		Isotope-Labeled Compounds Others
    16:0-18:0-16:0 TG-d5 is deuterium labeled 16:0-18:0-16:0 TG.
    16:0-18:0-16:0 <em>TG</em>-d5
  • HY-146915S
    17:0-17:1-17:0 TG-d5

    		Isotope-Labeled Compounds Others
    17:0-17:1-17:0 TG-d5 is deuterium labeled 17:0-17:1-17:0 TG.
    17:0-17:1-17:0 <em>TG</em>-d5
  • HY-146916S
    19:0-12:0-19:0 TG-d5

    		Isotope-Labeled Compounds Others
    19:0-12:0-19:0 TG-d5 is deuterium labeled 19:0-12:0-19:0 TG.
    19:0-12:0-19:0 <em>TG</em>-d5
  • HY-146917S
    20:0-20:1-20:0 TG-d5

    		Isotope-Labeled Compounds Others
    20:0-20:1-20:0 TG-d5 is deuterium labeled 20:0-20:1-20:0 TG.
    20:0-20:1-20:0 <em>TG</em>-d5
  • HY-146799S
    15:0-18:1-15:0 TG-d7

    		Isotope-Labeled Compounds Others
    15:0-18:1-15:0 TG-d7 is deuterium labeled 15:0-18:1-15:0 TG.
    15:0-18:1-15:0 <em>TG</em>-d7
  • HY-146913S
    15:0-18:1-15:0 TG-d5

    		Isotope-Labeled Compounds Others
    15:0-18:1-15:0 TG-d5 is deuterium labeled 15:0-18:1-15:0 TG.
    15:0-18:1-15:0 <em>TG</em>-d5
  • HY-163166S
    18:1-19:2-18:1 TG-d5

    		Isotope-Labeled Compounds Others
    18:1-19:2-18:1 TG-d5 is a deuterium labeled 18:1-19:2-18:1 TG .
    18:1-19:2-18:1 <em>TG</em>-d5
  • HY-163163S
    18:1-21:2-18:1 TG-d5

    		Isotope-Labeled Compounds Others
    18:1-21:2-18:1 TG-d5 is deuterium labeled 18:1-21:2-18:1 TG .
    18:1-21:2-18:1 <em>TG</em>-d5
  • HY-N8214
    Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside

    		Others Cardiovascular Disease
    Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside is a bioactive constituent that can be found in the seeds of Lepidium apetalum Willd. Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside exhibits significant triglyceride (TG)-lowering effects in HepG2 cells .
    Isorhamnetin 3-O-β-D-glucose-7-O-β-D-gentiobioside
  • HY-15166A
    (E/Z)-Zotiraciclib hydrochloride
    5 Publications Verification

    (E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride

    		 CDK JAK FLT3 Cancer
    (E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent CDK2, JAK2, and FLT3 inhibitor .
    (E/Z)-Zotiraciclib hydrochloride
  • HY-23199
    H2-003

    		Acyltransferase Metabolic Disease
    H2-003 is a selective human DGAT2 inhibitor that inhibits triglyceride (TG) biosynthesis. H2-003 also effectively inhibits lipid droplet formation in 3T3-L1 cells. H2-003 can be used for research on DGAT2 and TG-related metabolic diseases .
    H2-003
  • HY-163164S
    18:1-17:1-18:1 TG-d5

    		Isotope-Labeled Compounds Others
    18:1-17:1-18:1 TG-d5, 1,3-dioleoyl-2-heptadec-10Z-enoyl-glycerol-d5, is a deuterated substance .
    18:1-17:1-18:1 <em>TG</em>-d5
  • HY-N7907
    Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside

    		Others Metabolic Disease
    Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside is a natural product that can be obtained from sphaerophysa salsula. Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside inhibits triglyceride (TG) accumulation in 3T3-L1 adipocytes .
    Myricetin-3-O-β-D-xylopyranosyl-(1→2)-β-D-glucopyranoside

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: